Project Grant R41CA213711

This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...

This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $155,250 to Virginia Commonwealth University (VCU) to define the role of the protein PLK1 in the development of hepatocellular carcinoma (liver cancer) using a genetically modified mouse model. The study aims to establish a liver-specific PLK1 transgenic mouse model to unambiguously determine whether elevated PLK1 levels drive liver cancer progression. Findings from this project are...

This federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Blood Cell Technologies LLC to develop second-generation BLVRB inhibitors for treating chemotherapy-induced thrombocytopenia (CIT). The key objectives are to: 1) optimize the potency and drug-like properties of the lead first-generation BLVRB inhibitor compound through in silico modeling, 2) evaluate the therapeutic range and pharmacokinetics of the lead-optimized...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $186,000.00 to The Institute For Cancer Research (ICR) to conduct pilot studies on a new tumor-targeted AURKA (Aurora-A Kinase) inhibitor called NN-01-195. The goal is to investigate the feasibility and potential of this novel chimeric compound, which fuses an HSP90 inhibitor with an AURKA inhibitor, as a cancer treatment approach. The proposed research aims to evaluate the...

The Mayo Clinic will identify novel protein biomarkers and targets to overcome PARP inhibitor resistance under a $954,000 project grant from the Department of the Army Medical Command. The grant was awarded on June 15, 2021 with a completion date of June 14, 2025 under the Military Medical Research and Development program (CFDA 12.420). This program supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical solutions for...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $400,000 to Senex Biotechnology Inc. to develop a nanoparticle formulation of a mediator kinase inhibitor drug candidate, SNX631-6, for the treatment of peritoneal ovarian cancer metastases. The goal is to optimize the nanoparticle formulation for improved pharmacokinetics and efficacy compared to oral administration when delivered intraperitoneally. The project will assess the...

The National Cancer Institute (NCI) awarded a $151,000 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Medical University of South Carolina (MUSC) to investigate the role of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The project aims to: 1) Define essential genes for the polyploid cancer cell lifecycle and its critical transition stages using CRISPR-Cas9 screening, and 2) Determine the expression of putative polyploid cancer...

This federal Project Grant award for $237,724, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research by New York University School of Medicine to develop novel antibody-based therapeutics targeting the plasma membrane vacuolar ATPase (pmvATPase) as an anti-cancer therapy. The long-term goal is to validate pmvATPase as a therapeutic target and create selective antibodies that inhibit its activity, which is associated with...

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) supports research to investigate how inhibition of the ABL kinase enzyme can sensitize small cell lung cancer (SCLC) to metabolic disruptions, leading to cell death. The $165,196 award to Duke University was made on December 1, 2024 and is scheduled for completion by May 31, 2026. The researchers have performed a CRISPR/Cas9 screen to identify combination therapy targets that synergize with the ABL...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $633,705 to the Mayo Clinic in Rochester, Minnesota to investigate mechanisms underlying resistance to PARP inhibitor (PARPi) drugs in prostate cancer. The research aims to identify strategies to overcome PARPi resistance, with a focus on the role of the NSD3S histone methyltransferase isoform in regulating DNA replication dynamics and contributing to PARPi resistance. The award...